{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:49Z","timestamp":1794893629729,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01281-1","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:48:25Z","timestamp":1744825705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PDL1-expressing macrophages infiltrate diffuse large B-cell lymphoma and promote lymphoma growth in a MYC-driven experimental model"],"prefix":"10.1038","volume":"15","author":[{"given":"Ningxuan","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa-Sindi","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8870-164X","authenticated-orcid":false,"given":"Kristin","family":"Stirm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1826-3952","authenticated-orcid":false,"given":"Lydia","family":"Kirsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-6918","authenticated-orcid":false,"given":"Nicola","family":"Aceto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-5710","authenticated-orcid":false,"given":"Lothar C.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Detmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-2109","authenticated-orcid":false,"given":"Sarah","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Greter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-3819","authenticated-orcid":false,"given":"Alexandar","family":"Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-8276","authenticated-orcid":false,"given":"Anne","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"1281_CR1","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1281_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481\u201394.e15.","journal-title":"Cell"},{"key":"1281_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ccell.2024.02.001","volume":"42","author":"AJ Radtke","year":"2024","unstructured":"Radtke AJ, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, et al. Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients. Cancer Cell. 2024;42:444\u201363.e10.","journal-title":"Cancer Cell"},{"key":"1281_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"1281_CR5","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39:1643\u201353.e3.","journal-title":"Cancer Cell"},{"key":"1281_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","volume":"3","author":"G Han","year":"2022","unstructured":"Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 2022;3:428\u201343.","journal-title":"Blood Cancer Discov"},{"key":"1281_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.826594","volume":"13","author":"P Mondello","year":"2022","unstructured":"Mondello P, Ansell SM, Nowakowski GS. Immune epigenetic crosstalk between malignant B cells and the tumor microenvironment in B cell lymphoma. Front Genet. 2022;13:826594.","journal-title":"Front Genet"},{"key":"1281_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2019000847","volume":"135","author":"J Kline","year":"2020","unstructured":"Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135:523\u201333.","journal-title":"Blood"},{"key":"1281_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1182\/blood.2023021000","volume":"143","author":"C Laurent","year":"2024","unstructured":"Laurent C, Dietrich S, Tarte K. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm. Blood. 2024;143:1080\u201390.","journal-title":"Blood"},{"key":"1281_CR10","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1182\/bloodadvances.2023009813","volume":"7","author":"KT Wright","year":"2023","unstructured":"Wright KT, Weirather JL, Jiang S, Kao KZ, Sigal Y, Giobbie-Hurder A, et al. Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging. Blood Adv. 2023;7:4633\u201346.","journal-title":"Blood Adv"},{"key":"1281_CR11","doi-asserted-by":"crossref","unstructured":"Ivanova VS, Vela V, Dirnhofer S, Dobbie M, Stenner F, Knoblich J, et al. Molecular characterization and genetic subclassification comparison of diffuse large B-cell lymphoma (DLBCL)\u2014real-life experience with 74 cases. Pathobiology. 2023;91:245\u201353.","DOI":"10.1159\/000535938"},{"key":"1281_CR12","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/1078-0432.CCR-05-2135","volume":"12","author":"A Tzankov","year":"2006","unstructured":"Tzankov A, Gschwendtner A, Augustin F, Fiegl M, Obermann EC, Dirnhofer S, et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006;12:2125\u201332.","journal-title":"Clin Cancer Res"},{"key":"1281_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533\u20138.","journal-title":"Nature"},{"key":"1281_CR14","doi-asserted-by":"crossref","unstructured":"Stirm K, Leary P, Wust D, Stark D, Joller N, Karakus U, et al. Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models. J Immunother Cancer. 2023;11:e006263.","DOI":"10.1136\/jitc-2022-006263"},{"key":"1281_CR15","doi-asserted-by":"crossref","unstructured":"Sekine T, Perez-Potti A, Nguyen S, Gorin JB, Wu VH, Gostick E, et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci Immunol. 2020;5:eaba7918.","DOI":"10.1126\/sciimmunol.aba7918"},{"key":"1281_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly KA, Kuchroo M, Venkat A, Khatun A, Wang J, William I, et al. A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol. 2021;6:eabg7836.","journal-title":"Sci Immunol"},{"key":"1281_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-017-0438-7","volume":"10","author":"D Juskevicius","year":"2017","unstructured":"Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38\/07 prospective clinical trial cohort. J Hematol Oncol. 2017;10:70.","journal-title":"J Hematol Oncol"},{"key":"1281_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80376-0","volume":"11","author":"L Pedrosa","year":"2021","unstructured":"Pedrosa L, Fernandez-Miranda I, Perez-Callejo D, Quero C, Rodriguez M, Martin-Acosta P, et al. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Sci Rep. 2021;11:1886.","journal-title":"Sci Rep"},{"key":"1281_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood.2023021002","volume":"143","author":"L Cerchietti","year":"2024","unstructured":"Cerchietti L. Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma. Blood. 2024;143:1101\u201311.","journal-title":"Blood"},{"key":"1281_CR20","doi-asserted-by":"crossref","unstructured":"Ivanova VS, Menter T, Cui N, Leary P, Zinner C, Halter JP, et al. Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas. Br J Haematol. 2025;206:484\u2013504.","DOI":"10.1111\/bjh.19952"},{"key":"1281_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj5097","volume":"8","author":"MM Wattenberg","year":"2023","unstructured":"Wattenberg MM, Coho H, Herrera VM, Graham K, Stone ML, Xue Y, et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci Immunol. 2023;8:eadj5097.","journal-title":"Sci Immunol"},{"key":"1281_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41590-023-01430-3","volume":"24","author":"PS Liu","year":"2023","unstructured":"Liu PS, Chen YT, Li X, Hsueh PC, Tzeng SF, Chen H, et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat Immunol. 2023;24:452\u201362.","journal-title":"Nat Immunol"},{"key":"1281_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-015-0168-7","volume":"8","author":"A Tzankov","year":"2015","unstructured":"Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, et al. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38\/07 study. J Hematol Oncol. 2015;8:70.","journal-title":"J Hematol Oncol"},{"key":"1281_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Takata K, Beguelin W, Duns G, Mottok A, Farinha P, et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9:546\u201363.","journal-title":"Cancer Discov"},{"key":"1281_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj7412","volume":"379","author":"C Mlynarczyk","year":"2023","unstructured":"Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, et al. BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Science. 2023;379:eabj7412.","journal-title":"Science"},{"key":"1281_CR26","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","volume":"127","author":"K Georgiou","year":"2016","unstructured":"Georgiou K, Chen L, Berglund M, Ren W, de Miranda NF, Lisboa S, et al. Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. Blood. 2016;127:3026\u201334.","journal-title":"Blood"},{"key":"1281_CR27","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1182\/blood-2018-10-879015","volume":"133","author":"J Godfrey","year":"2019","unstructured":"Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019;133:2279\u201390.","journal-title":"Blood"},{"key":"1281_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","volume":"54","author":"T Menter","year":"2016","unstructured":"Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016;54:17\u201324.","journal-title":"Hum Pathol"},{"key":"1281_CR29","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","volume":"7","author":"ZY Xu-Monette","year":"2019","unstructured":"Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoINT EXPRESSION IN THE TUMOR IMMUNE MICROENVIRONMEnt of DLBCL. Cancer Immunol Res. 2019;7:644\u201357.","journal-title":"Cancer Immunol Res"},{"key":"1281_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature. 2016;534:402\u20136.","journal-title":"Nature"},{"key":"1281_CR31","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193\u2013201.","journal-title":"Blood"},{"key":"1281_CR32","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","volume":"130","author":"CD Carey","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130:2420\u201330.","journal-title":"Blood"},{"key":"1281_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362:875\u201385.","journal-title":"N Engl J Med"},{"key":"1281_CR34","doi-asserted-by":"publisher","first-page":"2003533","DOI":"10.1080\/2162402X.2021.2003533","volume":"10","author":"K Stirm","year":"2021","unstructured":"Stirm K, Leary P, Bertram K, Nunez NG, Wust D, Boudesco C, et al. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. Oncoimmunology. 2021;10:2003533.","journal-title":"Oncoimmunology"},{"key":"1281_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481\u20139.","journal-title":"J Clin Oncol"},{"key":"1281_CR36","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s12032-011-0123-6","volume":"29","author":"QC Cai","year":"2012","unstructured":"Cai QC, Liao H, Lin SX, Xia Y, Wang XX, Gao Y, et al. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2012;29:2317\u201322.","journal-title":"Med Oncol"},{"key":"1281_CR37","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/bloodadvances.2018020602","volume":"3","author":"R McCord","year":"2019","unstructured":"McCord R, Bolen CR, Koeppen H, Kadel EE, 3rd, Oestergaard MZ, Nielsen T, et al. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019;3:531\u201340.","journal-title":"Blood Adv"},{"key":"1281_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihijarvi","year":"2015","unstructured":"Riihijarvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100:238\u201345.","journal-title":"Haematologica"},{"key":"1281_CR39","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","volume":"112","author":"V Minard-Colin","year":"2008","unstructured":"Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112:1205\u201313.","journal-title":"Blood"},{"key":"1281_CR40","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20040119","volume":"199","author":"J Uchida","year":"2004","unstructured":"Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659\u201369.","journal-title":"J Exp Med"},{"key":"1281_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s11684-022-0972-8","volume":"17","author":"Z Yan","year":"2023","unstructured":"Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, et al. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Front Med. 2023;17:699\u2013713.","journal-title":"Front Med"},{"key":"1281_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1094400","volume":"12","author":"M Lin","year":"2022","unstructured":"Lin M, Ma S, Sun L, Qin Z. The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: a meta-analysis. Front Oncol. 2022;12:1094400.","journal-title":"Front Oncol"},{"key":"1281_CR43","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","volume":"2","author":"C Keane","year":"2015","unstructured":"Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol. 2015;2:e445\u201355.","journal-title":"Lancet Haematol"},{"key":"1281_CR44","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","volume":"28","author":"M Autio","year":"2022","unstructured":"Autio M, Leivonen SK, Bruck O, Karjalainen-Lindsberg ML, Pellinen T, Leppa S. Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment. Clin Cancer Res. 2022;28:781\u201392.","journal-title":"Clin Cancer Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01281-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T17:48:28Z","timestamp":1744825708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01281-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1281"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01281-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"66"}}